These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 21116000

  • 1. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
    Borders EB, Bivona C, Medina PJ.
    Am J Health Syst Pharm; 2010 Dec 15; 67(24):2095-106. PubMed ID: 21116000
    [Abstract] [Full Text] [Related]

  • 2. Targeting mTOR pathways in human malignancies.
    Fasolo A, Sessa C.
    Curr Pharm Des; 2012 Dec 15; 18(19):2766-77. PubMed ID: 22475451
    [Abstract] [Full Text] [Related]

  • 3. Everolimus: side effect profile and management of toxicities in breast cancer.
    Paplomata E, Zelnak A, O'Regan R.
    Breast Cancer Res Treat; 2013 Aug 15; 140(3):453-62. PubMed ID: 23907751
    [Abstract] [Full Text] [Related]

  • 4. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J, Tian D.
    Curr Med Res Opin; 2014 Jan 15; 30(1):67-74. PubMed ID: 24028709
    [Abstract] [Full Text] [Related]

  • 5. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R.
    Expert Opin Pharmacother; 2011 May 15; 12(7):1143-55. PubMed ID: 21470068
    [Abstract] [Full Text] [Related]

  • 6. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A, Sessa C.
    Expert Opin Investig Drugs; 2011 Mar 15; 20(3):381-94. PubMed ID: 21299441
    [Abstract] [Full Text] [Related]

  • 7. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
    Lo Muzio L, Arena C, Troiano G, Villa A.
    Oral Dis; 2018 Mar 15; 24(1-2):144-171. PubMed ID: 29480626
    [Abstract] [Full Text] [Related]

  • 8. mTOR signaling and drug development in cancer.
    Dancey J.
    Nat Rev Clin Oncol; 2010 Apr 15; 7(4):209-19. PubMed ID: 20234352
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of everolimus in renal cell cancer.
    Amato R, Stepankiw M.
    Expert Opin Pharmacother; 2013 Jun 15; 14(9):1229-40. PubMed ID: 23578333
    [Abstract] [Full Text] [Related]

  • 10. Everolimus.
    Hasskarl J.
    Recent Results Cancer Res; 2018 Jun 15; 211():101-123. PubMed ID: 30069763
    [Abstract] [Full Text] [Related]

  • 11. Everolimus in renal cell carcinoma.
    Wang Y.
    Drugs Today (Barc); 2010 Aug 15; 46(8):557-66. PubMed ID: 20830316
    [Abstract] [Full Text] [Related]

  • 12. Common toxicities of mammalian target of rapamycin inhibitors.
    Soefje SA, Karnad A, Brenner AJ.
    Target Oncol; 2011 Jun 15; 6(2):125-9. PubMed ID: 21499766
    [Abstract] [Full Text] [Related]

  • 13. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.
    Cancer Chemother Pharmacol; 2013 May 15; 71(5):1297-307. PubMed ID: 23479136
    [Abstract] [Full Text] [Related]

  • 14. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug 15; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 15. The applicability of mTOR inhibition in solid tumors.
    Konings IR, Verweij J, Wiemer EA, Sleijfer S.
    Curr Cancer Drug Targets; 2009 May 15; 9(3):439-50. PubMed ID: 19442061
    [Abstract] [Full Text] [Related]

  • 16. Temsirolimus: a safety and efficacy review.
    Bukowski RM.
    Expert Opin Drug Saf; 2012 Sep 15; 11(5):861-79. PubMed ID: 22861825
    [Abstract] [Full Text] [Related]

  • 17. Everolimus.
    Hasskarl J.
    Recent Results Cancer Res; 2014 Sep 15; 201():373-92. PubMed ID: 24756805
    [Abstract] [Full Text] [Related]

  • 18. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
    Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM.
    BJU Int; 2014 Mar 15; 113(3):376-82. PubMed ID: 24053120
    [Abstract] [Full Text] [Related]

  • 19. Differentiating mTOR inhibitors in renal cell carcinoma.
    Pal SK, Quinn DI.
    Cancer Treat Rev; 2013 Nov 15; 39(7):709-19. PubMed ID: 23433636
    [Abstract] [Full Text] [Related]

  • 20. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA, Kim M, Wenger SD, O'Bryant CL.
    Ann Pharmacother; 2012 Sep 15; 46(9):1212-9. PubMed ID: 22947595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.